Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when LGND files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsLigand amends XOMA Royalty merger agreement to add holding company structure
Filed May 18, 2026 · Period ending May 16, 2026 · ~1 min read
Key Changes
-
high
Ligand and XOMA Royalty amended their April 27 merger agreement to add XOMA Royalty Holdings Corporation (HoldCo), a newly formed Nevada entity, as a party to facilitate a holding company reorganization before the merger closes.
Item 1.01 verify on EDGAR → -
medium
Under the revised structure, Ligand's merger subsidiary will merge with HoldCo, which will become a wholly owned subsidiary of Ligand upon completion, rather than merging directly with XOMA Royalty.
Item 1.01 verify on EDGAR → -
medium
The original merger agreement was signed April 27, 2026 and still requires XOMA Royalty stockholder approval and regulatory clearances before closing.
Item 1.01 verify on EDGAR →
Summary
Ligand Pharmaceuticals amended its pending merger agreement with XOMA Royalty Corporation to restructure the transaction through a newly formed holding company. The May 16 amendment adds XOMA Royalty Holdings Corporation as a party and changes the merger mechanics so Ligand's subsidiary will merge with this new holding company rather than directly with XOMA Royalty.
This type of holding company reorganization is a common corporate structure adjustment that can provide tax or operational benefits, though the 8-K doesn't specify the rationale. For Ligand shareholders, this amendment represents a technical change to deal structure rather than a material shift in transaction terms or valuation. The core economics of the April 27 merger agreement appear unchanged.
However, investors should watch for the definitive proxy materials that will provide full details on the amended transaction structure and any implications for the combined company. The deal still requires XOMA stockholder approval and regulatory clearances before closing.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 16, 2026, XOMA Royalty, Ligand and the Merger Sub entered into Amendment No. 1 to the Agreement and Plan of Merger (“Amendment No. 1”) which, among other things, adds HoldCo as a party to the Merger Agreement.
Ligand Pharmaceuticals and XOMA Royalty amended their previously announced merger agreement to add XOMA Royalty Holdings Corporation (HoldCo) as a party. HoldCo is a newly formed Nevada corporation and wholly-owned subsidiary of XOMA Royalty created specifically to effect a holding company reorganization. Under the amended structure, Ligand's merger subsidiary will merge with HoldCo, which will become a wholly owned subsidiary of Ligand.
Added in current filing · verify on EDGAR →
on April 27, 2026, Ligand Pharmaceuticals Incorporated, a Delaware corporation (“Ligand”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among Ligand, XOMA Royalty Corporation, a Nevada corporation (“XOMA Royalty”), and Flex Merger Sub, Inc., a Nevada corporation and wholly-owned subsidiary of Ligand (“Merger Sub”), pursuant to which, and upon the terms and subject to the conditions thereof, including, without limitation, effecting the Holding Company Reorganization (as defined below), Merger Sub will merge with and into a newly formed Nevada corporation, XOMA Royalty Holdings Corporation (“HoldCo”), (the “Merger”), with HoldCo surviving the Merger as a wholly owned subsidiary of Ligand.
The amendment relates to a merger agreement originally signed on April 27, 2026, under which Ligand agreed to acquire XOMA Royalty through a merger structure. The transaction requires XOMA Royalty stockholder approval and regulatory clearances, with definitive proxy materials to be filed with the SEC.
Event · Item 9.01 — Financial Statements and Exhibits
Item 9.01 — Financial Statements and Exhibits filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Amendment No. 1 to the Agreement and Plan of Merger, dated as of May 16, 2026, by and among XOMA Royalty Corporation, XOMA Royalty Holdings Corporation, Ligand Pharmaceuticals Incorporated and Flex Merger Sub, Inc.
Ligand disclosed an amendment to a previously announced merger agreement involving XOMA Royalty Corporation, XOMA Royalty Holdings Corporation, and Flex Merger Sub, Inc. The 8-K does not provide details on what terms were modified in Amendment No. 1, but the existence of an amendment indicates changes to the original merger terms agreed upon by the parties.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify